{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T04:03:31Z","timestamp":1771905811342,"version":"3.50.1"},"reference-count":77,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1093\/ecco-jcc\/jjv033","type":"journal-article","created":{"date-parts":[[2015,2,17]],"date-time":"2015-02-17T02:21:11Z","timestamp":1424139671000},"page":"356-366","source":"Crossref","is-referenced-by-count":51,"title":["Introducing Vedolizumab to Clinical Practice: Who, When, and How?"],"prefix":"10.1093","volume":"9","author":[{"given":"RV","family":"Bryant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WJ","family":"Sandborn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SPL","family":"Travis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,2,16]]},"reference":[{"key":"key\n\t\t\t\t20170424190141_CIT0001","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1124\/jpet.109.153973","article-title":"The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases","volume":"330","author":"Soler","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"key\n\t\t\t\t20170424190141_CIT0002","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0092-8674(93)90305-A","article-title":"Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1","volume":"74","author":"Berlin","year":"1993","journal-title":"Cell"},{"key":"key\n\t\t\t\t20170424190141_CIT0003","first-page":"97","article-title":"Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue","volume":"151","author":"Briskin","year":"1997","journal-title":"Am J Pathol"},{"key":"key\n\t\t\t\t20170424190141_CIT0004","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1053\/gast.1996.v111.pm8898653","article-title":"Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7","volume":"111","author":"Hesterberg","year":"1996","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170424190141_CIT0005","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.4049\/jimmunol.158.5.2099","article-title":"Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells","volume":"158","author":"Picarella","year":"1997","journal-title":"J Immunol"},{"key":"key\n\t\t\t\t20170424190141_CIT0006","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1002\/ibd.22940","article-title":"Exclusive antagonism of the alpha4 beta7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates","volume":"18","author":"Fedyk","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170424190141_CIT0007","doi-asserted-by":"crossref","first-page":"704","DOI":"10.7326\/M13-2403","article-title":"Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis","volume":"160","author":"Danese","year":"2014","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170424190141_CIT0008","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1053\/j.gastro.2014.08.044","article-title":"Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases","volume":"147","author":"Danese","year":"2014","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170424190141_CIT0009","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170424190141_CIT0010","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170424190141_CIT0011","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn\u2019s disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170424190141_CIT0012","first-page":"CD007571","article-title":"Vedolizumab for induction and maintenance of remission in ulcerative colitis","volume":"8","author":"Bickston","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20170424190141_CIT0013","doi-asserted-by":"crossref","first-page":"S-113","DOI":"10.1016\/S0016-5085(13)60410-2","article-title":"Integrated safety analysis of vedolizumab for the treatment of ulcerative colitis or Crohn\u2019s disease","volume":"144(","author":"Colombel","year":"2013","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170424190141_CIT0014","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/j.1365-2036.2010.04262.x","article-title":"Clinically significant liver injury in patients treated with natalizumab","volume":"31","author":"Bezabeh","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170424190141_CIT0015","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1177\/2050640614550672","article-title":"Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same?","volume":"2","author":"Raine","year":"2014","journal-title":"United European Gastroenterol J"},{"key":"key\n\t\t\t\t20170424190141_CIT0016","doi-asserted-by":"crossref","first-page":"S502","DOI":"10.14309\/00000434-201310001-01674","article-title":"Long-term safety of vedolizumab for the treatment of ulcerative colitis or Crohn\u2019s disease","volume":"108(","author":"Colombel","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170424190141_CIT0017","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/gutjnl-2014-307127","article-title":"Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results","volume":"64","author":"Wyant","year":"2015","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170424190141_CIT0018","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1056\/NEJMe058122","article-title":"Progressive multifocal leukoencephalopathy and natalizumab\u2014unforeseen consequences","volume":"353","author":"Berger","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170424190141_CIT0019","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2013.08.011","article-title":"Vedolizumab, a monoclonal antibody to the gut homing alpha4beta7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype","volume":"264","author":"Milch","year":"2013","journal-title":"J Neuroimmunol"},{"key":"key\n\t\t\t\t20170424190141_CIT0020","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archneur.63.10.1383","article-title":"Altered CD4+\/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis","volume":"63","author":"Stuve","year":"2006","journal-title":"Arch Neurol"},{"key":"key\n\t\t\t\t20170424190141_CIT0021","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ana.20858","article-title":"Immune surveillance in multiple sclerosis patients treated with natalizumab","volume":"59","author":"Stuve","year":"2006","journal-title":"Ann Neurol"},{"key":"key\n\t\t\t\t20170424190141_CIT0022","article-title":"Vedolizumab for treating moderately to severely active ulcerative colitis, 2014","author":"National Institute for Health and Care Excellence"},{"key":"key\n\t\t\t\t20170424190141_CIT0023","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170424190141_CIT0024","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170424190141_CIT0025","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170424190141_CIT0026","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170424190141_CIT0027","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170424190141_CIT0028","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170424190141_CIT0029","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170424190141_CIT0030","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170424190141_CIT0031","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170424190141_CIT0032","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cgh.2011.04.031","article-title":"Certolizumab pegol for active Crohn\u2019s disease: a placebo-controlled, randomized trial","volume":"9","author":"Sandborn","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170424190141_CIT0033","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn\u2019s disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170424190141_CIT0034","article-title":"Comparative effectiveness of immunosuppressant and biologics for inducing and maintaining remission in Crohn\u2019s disease: a network meta-analysis","author":"Hazlewood","journal-title":"Gastroenterology 2015;148:344\u201354"},{"key":"key\n\t\t\t\t20170424190141_CIT0035","first-page":"1880","article-title":"Cause-specific mortality and 30-year relative survival of Crohn\u2019s disease and ulcerative colitis","volume":"19","author":"Selinger","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170424190141_CIT0036","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.crohns.2010.02.001","article-title":"The pattern and outcome of acute severe colitis","volume":"4","author":"Dinesen","year":"2010","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20170424190141_CIT0037","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","article-title":"Cortisone in ulcerative colitis; final report on a therapeutic trial","volume":"2","author":"Truelove","year":"1955","journal-title":"Br Med J"},{"key":"key\n\t\t\t\t20170424190141_CIT0038","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2006.09.033","article-title":"Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression","volume":"5","author":"Turner","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170424190141_CIT0039","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cgh.2010.09.016","article-title":"A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease","volume":"9","author":"Kotlyar","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170424190141_CIT0040","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cgh.2010.09.026","article-title":"Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease","volume":"9","author":"Cottone","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170424190141_CIT0041","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease","volume":"134","author":"Toruner","year":"2008","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170424190141_CIT0042","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"8","author":"Rahier","year":"2014","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20170424190141_CIT0043","doi-asserted-by":"crossref","first-page":"509","DOI":"10.5946\/ce.2014.47.6.509","article-title":"Colon cancer screening and surveillance in inflammatory bowel disease","volume":"47","author":"Bae","year":"2014","journal-title":"Clin Endosc"},{"key":"key\n\t\t\t\t20170424190141_CIT0044","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1053\/j.gastro.2013.03.044","article-title":"Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease","volume":"145","author":"Beaugerie","year":"2013","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170424190141_CIT0045","article-title":"Briefing document for the joint meeting of the gastrointestinal drugs advisory committee and drug safety and risk management advisory committee. Vedolizumab for the treatment of ulcerative colitis and Crohn\u2019s disease BLA #125507 and BMA #125476 July 2013","author":"Takeda"},{"key":"key\n\t\t\t\t20170424190141_CIT0046","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(13)60096-3","article-title":"Primary sclerosing cholangitis","volume":"382","author":"Hirschfield","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170424190141_CIT0047","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/gut.2004.046615","article-title":"PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis","volume":"54","author":"Loftus","year":"2005","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170424190141_CIT0048","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1053\/jhep.2001.24231","article-title":"MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease)","volume":"33","author":"Grant","year":"2001","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20170424190141_CIT0049","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.24085","article-title":"Regulation of mucosal addressin cell adhesion molecule 1 expression in human and mice by vascular adhesion protein 1 amine oxidase activity","volume":"53","author":"Liaskou","year":"2011","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t20170424190141_CIT0050","doi-asserted-by":"crossref","first-page":"G1257","DOI":"10.1152\/ajpgi.00266.2007","article-title":"CCL25 and CCL28 promote alpha4 beta7-integrin-dependent adhesion of lymphocytes to MAdCAM-1 under shear flow","volume":"294","author":"Miles","year":"2008","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"key\n\t\t\t\t20170424190141_CIT0051","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1084\/jem.20041035","article-title":"Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis","volume":"200","author":"Eksteen","year":"2004","journal-title":"J Exp Med"},{"key":"key\n\t\t\t\t20170424190141_CIT0052","first-page":"CD000478","article-title":"Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis","volume":"9","author":"Timmer","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20170424190141_CIT0053","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/gut.2005.068809","article-title":"Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis","volume":"55","author":"Ardizzone","year":"2006","journal-title":"Gut"},{"key":"key\n\t\t\t\t20170424190141_CIT0054","first-page":"CD006618","article-title":"Methotrexate for induction of remission in ulcerative colitis","volume":"8","author":"Chande","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t20170424190141_CIT0055","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1097\/MIB.0b013e318281f28f","article-title":"Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients","volume":"19","author":"Chaparro","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170424190141_CIT0056","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1053\/j.gastro.2013.04.048","article-title":"Early administration of azathioprine vs conventional management of Crohn\u2019s disease: a randomized controlled trial","volume":"145","author":"Cosnes","year":"2013","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170424190141_CIT0057","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1053\/j.gastro.2013.06.009","article-title":"Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn\u2019s disease","volume":"145","author":"Panes","year":"2013","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170424190141_CIT0058","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn\u2019s disease: an open randomised trial","volume":"371","author":"D\u2019Haens","year":"2008","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170424190141_CIT0059","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1873-9946(14)60005-2","article-title":"Early combined immunosuppression for the management of Crohn\u2019s disease: A community-based cluster randomized trial","volume":"8","author":"Khanna","year":"2014","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20170424190141_CIT0060","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/ajg.2010.78","article-title":"Increased response and remission rates in short-duration Crohn\u2019s disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data","volume":"105","author":"Schreiber","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170424190141_CIT0061","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/ibd.21506","article-title":"Development of the Crohn\u2019s disease digestive damage score, the Lemann score","volume":"17","author":"Pariente","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170424190141_CIT0062","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: recommendations of an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t20170424190141_CIT0063","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1002\/ibd.22839","article-title":"Ulcerative colitis as a progressive disease: the forgotten evidence","volume":"18","author":"Torres","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170424190141_CIT0064","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/ajg.2009.579","article-title":"The natural history of adult Crohn\u2019s disease in population-based cohorts","volume":"105","author":"Peyrin-Biroulet","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t20170424190141_CIT0065","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.cgh.2008.06.007","article-title":"Treatment of active Crohn\u2019s disease with MLN0002, a humanized antibody to the alpha4beta7 integrin","volume":"6","author":"Feagan","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t20170424190141_CIT0066","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa042982","article-title":"Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin","volume":"352","author":"Feagan","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170424190141_CIT0067","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1517\/14712598.2013.770835","article-title":"Vedolizumab for Crohn\u2019s disease","volume":"13","author":"Mosli","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"key\n\t\t\t\t20170424190141_CIT0068","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1097\/MIB.0b013e318281f538","article-title":"Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease","volume":"19","author":"Parikh","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170424190141_CIT0069","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/ibd.20899","article-title":"Incidence and clinical significance of immunogenicity to infliximab in Crohn\u2019s disease: a critical systematic review","volume":"15","author":"Cassinotti","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170424190141_CIT0070","first-page":"S30","article-title":"Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies","volume":"8(","author":"Rosario","year":"2014","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20170424190141_CIT0071","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/apt.12639","article-title":"Review article: anti-adhesion therapies for inflammatory bowel disease","volume":"39","author":"Lobaton","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t20170424190141_CIT0072","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/ibd.21896","article-title":"Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study","volume":"18","author":"Parikh","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20170424190141_CIT0073","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170424190141_CIT0074","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.crohns.2011.02.005","article-title":"Managing the long term care of inflammatory bowel disease patients: The cost to European health care providers","volume":"5","author":"Buchanan","year":"2011","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t20170424190141_CIT0075","doi-asserted-by":"crossref","first-page":"A874","DOI":"10.1016\/S0016-5085(00)85637-1","article-title":"An ascending dose of a humanized A4B7 antibody in ulcerative colitis","volume":"118(","author":"Feagan","year":"2000","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170424190141_CIT0076","doi-asserted-by":"crossref","first-page":"A25","DOI":"10.1016\/S0016-5085(03)80125-7","article-title":"Efficacy and safety of a humanized a4b7 antibody in active Crohn\u2019s disease","volume":"124(","author":"Feagan","year":"2003","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t20170424190141_CIT0500"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/9\/4\/356\/13746567\/jjv033.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T06:58:23Z","timestamp":1717743503000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-lookup\/doi\/10.1093\/ecco-jcc\/jjv033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,16]]},"references-count":77,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,2,16]]},"published-print":{"date-parts":[[2015,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjv033","relation":{},"ISSN":["1876-4479","1873-9946"],"issn-type":[{"value":"1876-4479","type":"electronic"},{"value":"1873-9946","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2,16]]}}}